Major cost savings associated with biologic dose reduction in patients with inflammatory arthritis.

Hdl Handle:
http://hdl.handle.net/10147/559162
Title:
Major cost savings associated with biologic dose reduction in patients with inflammatory arthritis.
Authors:
Murphy, C L; Awan, S; Sullivan, M O; Chavrimootoo, S; Bannon, C; Martin, L; Duffy, T; Murphy, E; Barry, M
Citation:
Major cost savings associated with biologic dose reduction in patients with inflammatory arthritis. 2015, 108 (1):19-21 Ir Med J
Publisher:
Irish Medical Journal
Journal:
Irish medical journal
Issue Date:
Jan-2015
URI:
http://hdl.handle.net/10147/559162
PubMed ID:
25702349
Abstract:
The purpose of this study was to explore whether patients with Inflammatory Arthritis (IA) (Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS)) would remain in remission following a reduction in biologic dosing frequency and to calculate the cost savings associated with dose reduction. This prospective non-blinded non-randomised study commenced in 2010. Patients with Inflammatory Arthritis being treated with a biologic agent were screened for disease activity. A cohort of those in remission according to standardized disease activity indices (DAS28 < 2.6, BASDAI < 4) was offered a reduction in dosing frequency of two commonly used biologic therapies (etanercept 50 mg once per fortnight instead of weekly, adalimumab 40 mg once per month instead of fortnightly). Patients were assessed for disease activity at 3, 6, 12, 18 and 24 months following reduction in dosing frequency. Cost saving was calculated. 79 patients with inflammatory arthritis in remission were recruited. 57% had rheumatoid arthritis (n = 45), 13% psoriatic arthritis (n = 10) and 30% ankylosing spondylitis (n = 24). 57% (n = 45) were taking etanercept and 43% (n = 34) adalimumab. The percentage of patients in remission at 24 months was 56% (n = 44). This resulted in an actual saving to the state of approximately 600,000 euro over two years. This study demonstrates the reduction in biologic dosing frequency is feasible in Inflammatory Arthritis. There was a considerable cost saving at two years. The potential for major cost savings in biologic usage should be pursued further.
Item Type:
Article
Language:
en
Keywords:
MEDICINES; ARTHRITIS
MeSH:
Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Arthritis; Cost Savings; Female; Humans; Immunoglobulin G; Male; Middle Aged; Prospective Studies; Receptors, Tumor Necrosis Factor; Treatment Outcome
ISSN:
0332-3102

Full metadata record

DC FieldValue Language
dc.contributor.authorMurphy, C Len
dc.contributor.authorAwan, Sen
dc.contributor.authorSullivan, M Oen
dc.contributor.authorChavrimootoo, Sen
dc.contributor.authorBannon, Cen
dc.contributor.authorMartin, Len
dc.contributor.authorDuffy, Ten
dc.contributor.authorMurphy, Een
dc.contributor.authorBarry, Men
dc.date.accessioned2015-07-07T14:27:23Zen
dc.date.available2015-07-07T14:27:23Zen
dc.date.issued2015-01en
dc.identifier.citationMajor cost savings associated with biologic dose reduction in patients with inflammatory arthritis. 2015, 108 (1):19-21 Ir Med Jen
dc.identifier.issn0332-3102en
dc.identifier.pmid25702349en
dc.identifier.urihttp://hdl.handle.net/10147/559162en
dc.description.abstractThe purpose of this study was to explore whether patients with Inflammatory Arthritis (IA) (Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS)) would remain in remission following a reduction in biologic dosing frequency and to calculate the cost savings associated with dose reduction. This prospective non-blinded non-randomised study commenced in 2010. Patients with Inflammatory Arthritis being treated with a biologic agent were screened for disease activity. A cohort of those in remission according to standardized disease activity indices (DAS28 < 2.6, BASDAI < 4) was offered a reduction in dosing frequency of two commonly used biologic therapies (etanercept 50 mg once per fortnight instead of weekly, adalimumab 40 mg once per month instead of fortnightly). Patients were assessed for disease activity at 3, 6, 12, 18 and 24 months following reduction in dosing frequency. Cost saving was calculated. 79 patients with inflammatory arthritis in remission were recruited. 57% had rheumatoid arthritis (n = 45), 13% psoriatic arthritis (n = 10) and 30% ankylosing spondylitis (n = 24). 57% (n = 45) were taking etanercept and 43% (n = 34) adalimumab. The percentage of patients in remission at 24 months was 56% (n = 44). This resulted in an actual saving to the state of approximately 600,000 euro over two years. This study demonstrates the reduction in biologic dosing frequency is feasible in Inflammatory Arthritis. There was a considerable cost saving at two years. The potential for major cost savings in biologic usage should be pursued further.en
dc.language.isoenen
dc.publisherIrish Medical Journalen
dc.rightsArchived with thanks to Irish medical journalen
dc.subjectMEDICINESen
dc.subjectARTHRITISen
dc.subject.meshAdulten
dc.subject.meshAnti-Inflammatory Agentsen
dc.subject.meshAntibodies, Monoclonal, Humanizeden
dc.subject.meshArthritisen
dc.subject.meshCost Savingsen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshImmunoglobulin Gen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshProspective Studiesen
dc.subject.meshReceptors, Tumor Necrosis Factoren
dc.subject.meshTreatment Outcomeen
dc.titleMajor cost savings associated with biologic dose reduction in patients with inflammatory arthritis.en
dc.typeArticleen
dc.identifier.journalIrish medical journalen
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.